Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom, GSK Pair Up to Create SNP Assay Portfolio

NEW YORK, Aug 29 – Sequenom said Wednesday it had entered an agreement with GlaxoSmithKline to create a SNP assay portfolio that would cover the entire human genome.

"Our immediate goal is to establish a SNP assay portfolio covering all SNPs,” Allen Roses, senior vice president of genetics research at GlaxoSmithKline, said in a statement.

“We are confident that Sequenom can complete a project of this magnitude within our timelines and utilize their technology to enable rapid use of whole genome SNP mapping," he added. 

Under the terms of the deal, GlaxoSmithKline of London will have access to Sequenom’s SNP assay portfolio. The pharmaceutical company then plans to select SNP candidates for genome-wide association studies.

San Diego-based Sequenom said the deal represented a “multimillion dollar agreement” but did not disclose exact terms.

The companies were not immediately available to discuss the announcement.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.